Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | RPA1 | P27694 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229161 | 0.94 | RXFP1 (0.36) | RXFP1BACE1KMT2AMEN1POLB | |
| SCHEMBL4241068 | 0.91 | HCAR3 (0.35) | RXFP1KMT2AMEN1POLB | |
| SCHEMBL4228487 | 0.88 | BACE1 (0.40) | BACE1BACE2CTSD | |
| SCHEMBL4236600 | 0.88 | ABHD10 (0.34) | RXFP1BACE1KMT2AMEN1 | |
| SCHEMBL4238987 | 0.83 | BACE1 (0.45) | BACE1KMT2AMEN1POLBBACE2 | |
| SCHEMBL4237695 | 0.83 | BACE1 (0.42) | BACE1BACE2CTSD | |
| SCHEMBL4232063 | 0.83 | BACE1 (0.39) | BACE1BACE2CTSD | |
| SCHEMBL4232956 | 0.82 | POLB (0.36) | BACE1KMT2AMEN1POLBBACE2 | |
| SCHEMBL4232580 | 0.82 | KMT2A (0.40) | BACE1KMT2AMEN1POLBBACE2 | |
| SCHEMBL4232737 | 0.81 | BACE1 (0.38) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | claimed |
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | PSEN2, MAPT, PSEN1 | RXFP1 4065/4885BACE1 7/4885TSHR 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.